) Ojjaara (momelotinib) is the only approved treatment for newly diagnosed and previously treated myelofibrosis patients[i] who have moderate to severe anemia and other key manifestations associated with the disease.[ii] This approval underscores GSK's commitment to help drive progress for people living with complex blood... read full story